Erasca, Inc. (ERAS) Financials

ERAS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 435.1 million 73.2 million
March 31, 2026 461.2 million 67.7 million
Dec. 31, 2025 396.2 million 71.0 million
Sept. 30, 2025 420.4 million 72.5 million

ERAS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -27.3 million 9.6 million
March 31, 2026 -27.4 million 8.5 million
Dec. 31, 2025 -21.7 million 5.8 million
Sept. 30, 2025 -21.7 million 6.0 million

ERAS Net Income

No data available :(

ERAS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 268.7 million - 44.7 million
March 31, 2026 243.8 million - 46.0 million
Dec. 31, 2025 276.1 million - 47.1 million
Sept. 30, 2025 288.4 million - 43.4 million

ERAS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 311.3 million
March 31, 2026 304.3 million
Dec. 31, 2025 283.5 million
Sept. 30, 2025 283.7 million

ERAS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 8000 35.9 million 11.7 million -
March 31, 2026 36000 27.3 million 10.6 million -
Dec. 31, 2025 9000 23.2 million 9.4 million -
Sept. 30, 2025 6000 22.5 million 10.1 million -

ERAS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 723000
Dec. 31, 2025 - 743000
Sept. 30, 2025 - -

ERAS

Price: $18.38

52 week price:
1.33
24.28

Earnings Per Share: -0.96 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 393750

Market Capitalization: 6.5 billion

Links: